附近上门

spinoff raised $600 million in its first external funding round as the company looks to apply artificial intelligence to the drug development process.

The new round was led by with participation from . The London-based AI company will receive follow-on capital from existing investor .

Isomorphic was spun out of Google in 2021.

鈥淭his funding will further turbocharge the development of our next-generation AI drug design engine, help us advance our own programs into clinical development, and is a significant step forward towards our mission of one day solving all disease with the help of AI,鈥� founder and CEO Sir said in a statement.

AI and biotech

The round is just the latest big raise by a startup using AI in the pursuit of drug development.

Some notable raises in the past year-plus include San Francisco-based securing a $1 billion last spring led by and , and New York-based locking up $372 million in a Series D last summer led by .

The deal is also another big investment for Thrive, the New York-based investment firm co-founded by . The firm led 鈥� massive $10 billion raise at a $62 billion valuation last December. The deal was the largest venture capital raise of 2024 and one of the largest on record.

It also led 鈥檚 big $6.6 billion round in October that valued the company at $150 billion.

Related reading:

• Eye On AI: Thrive Capital鈥檚 Busy Year
• Databricks Raises $10B In 2024鈥檚 Largest Venture Funding Deal
• Healthcare And AI Is A Hot Combination For Startups

Illustration: